Transdermal Drug Delivery systems (also known as patches) by ProSolus, Inc. are created for multiple therapeutic categories.

We formulate and develop:

  • AB-rated Generics
  • 505(b)(2)
  • OTC products

All within our premier R&D and manufacturing facility, for optimal delivery technology.

We endeavor to execute agreements with pharmaceutical marketing companies seeking to develop and commercialize TDDs.

We evaluate FDA approved transdermal formulations to in-license and/or develop internally. Once engaged, we work with our partners to complete the requirements for clinical development and FDA approval.

For more information about putting a ProSolus partnership to work for you, please contact us.